Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter TB course could be Game-Changer for HIV patients

NCT ID NCT07608172

Disease control Sponsor: Shanghai Public Health Clinical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a shorter, 5-month combination of TB drugs works as well as the standard 6-month treatment for people with both HIV and drug-susceptible tuberculosis. It involves 148 participants with very weak immune systems (CD4 count under 100). The goal is to see if the shorter regimen can effectively treat TB while reducing side effects and treatment burden.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
isoniazid, rifapentine, moxifloxacin, pyrazinamide
What this could lead to
If successful, this could offer a shorter, more convenient treatment option for tuberculosis in people with advanced HIV, potentially improving adherence and outcomes.
What could go wrong
This is a relatively small, early-stage validation study. The shorter regimen may not be as effective or safe as the standard longer course, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 148 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years, able to understand and sign the informed consent form. * Confirmed HIV infection. * Baseline CD4+ T-lymphocyte count \< 100 cells/μL. * Confirmed active pulmonary tuberculosis. * Agree to receive antituberculosis treatment and antiretroviral therapy during the study period. Exclusion Criteria: * Known or suspected resistance to any of the drugs in the regimen, including rifapentine, moxifloxacin, rifampicin, isoniazid, ethambutol, and pyrazinamide. * Body weight \< 40 kg. * Received the current tuberculosis treatment for more than 7 days. * Complicated with tuberculous meningitis or other severe forms of tuberculosis. * Severe liver dysfunction (ALT or AST \> 5 times the upper limit of normal, ULN). - - Severe renal dysfunction (eGFR \< 30 mL/min/1.73m²). * Baseline electrocardiogram (ECG) showing QTc interval \> 500 ms. * Pregnant or lactating women. * Presence of other conditions deemed inappropriate for study participation by the investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug susceptible pulmonary tuberculosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease pulmonary tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug susceptible pulmonary tuberculosis Tuberculosis in HIV-infected individuals

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.